Market Place
Sourcing Support
Bellicum halts trials after serious adverse event, looks for `alternatives`
16 Mar 2023 //
ENDPTS
Bellicum Presents Early PI Results for BPX-601 in Prostate Cancer at ASCO GU
16 Feb 2023 //
GLOBENEWSWIRE
Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
31 Jan 2023 //
GLOBENEWSWIRE
Bellicum to Present Phase 1 Results for BPX-601 in Prostate Cancer at ASCO
19 Jan 2023 //
GLOBENEWSWIRE
Bellicum Announces Presentatioat on Abrogation of iC9 CAR T-Cell Toxicities
11 Dec 2022 //
GLOBENEWSWIRE
Bellicum Pharmaceuticals to Participate in the 2022 Cell & Gene Meeting
04 Oct 2022 //
GLOBENEWSWIRE
Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03 Oct 2022 //
GLOBENEWSWIRE
Bellicum to Participate in the H.C. Wainwright 24th Annual Global
01 Sep 2022 //
GLOBENEWSWIRE
Bellicum Reports Q2 2022 Rusult and Provides Operational Update
11 Aug 2022 //
GLOBENEWSWIRE
Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01 Jul 2022 //
GLOBENEWSWIRE
Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02 May 2022 //
GLOBENEWSWIRE
Bellicum Reports Q4 2021 Financial Results and Provides Operational Update
24 Mar 2022 //
GLOBENEWSWIRE
Bellicum Regains Compliance with Nasdaq Continued Listing Requirements
13 Dec 2021 //
GLOBENEWSWIRE
Bellicum and MD Anderson Announce Additional License Agreement for CaspaCIDe
01 Sep 2021 //
GLOBENEWSWIRE
Bellicum Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
26 Jul 2021 //
GLOBENEWSWIRE
Bellicum Enters License Agreement with UNC Lineberger
28 Jun 2021 //
GLOBENEWSWIRE
Bellicum Announces First Reported Use of CaspaCIDe® Safety
04 Mar 2021 //
GLOBENEWSWIRE
Bellicum Enrolls First Patient in Phase 1/2 Clinical Trial for BPX-603
10 Dec 2020 //
GLOBENEWSWIRE
Doctors Are Skeptical of Pricey Drug Given Emergency Approval for Covid
07 Dec 2020 //
NYTIMES
US FDA puts clinical hold on Bellicum’s prostate cancer therapy trial
07 Dec 2020 //
CLINICALTRIALSARENA
Bellicum Reports Clinical Hold Placed on BPX-601 Phase 1/2 Clinical Trial
07 Dec 2020 //
YAHOO
Bellicum Announces Closing of $25.0 M Underwritten Offering
03 Nov 2020 //
GLOBENEWSWIRE
Bellicum Pharmaceuticals to cut 79% of staff after disappointing trial data
30 Oct 2020 //
MARKETWATCH
Bellicum Announces Interim BPX-601 Data and Corporate Restructuring
29 Oct 2020 //
YAHOO
Out of jobs, a pair of early cell therapy executives went to Seoul,$70M
26 Jun 2020 //
ENDPTS
Bellicum Presents New Translational Data for BPX-601
24 Jan 2020 //
BELLICUM
Bellicum down 25% on potential T cell confusion issue with BPX-501
07 Nov 2019 //
SEEKINGAPLHA
Rosen Law Firm Announces Filing of Class Action Against Bellicum Pharma
21 Mar 2018 //
PRNEWSWIRE
Halted in US by FDA hold, Bellicum buoyed by some Positive numbers from its EU T cell
14 Mar 2018 //
FIERCE BIOTECH
Halted in US by FDA hold, Bellicum buoyed by some positive numbers
13 Mar 2018 //
ENDPTS
Bellicum bolsters R&D team with ex-Genentech executive
05 Feb 2018 //
FIERCE BIOTECH
3 Cases of Brain Damage Force the FDA to Slap a Hold on Bellicum`s Lead Drug
31 Jan 2018 //
BIOSPACE
Brain damage cases force an FDA hold on Bellicum’s lead cell therapy
31 Jan 2018 //
ENDPTS
TapImmune Brings on Former Bellicum Exec as New CEO
25 Sep 2017 //
BIOSPACE
Bellicum Pharma Announces Late-Breaking Presentation of Dual-Switch CAR-T
04 Apr 2017 //
GLOBENEWSWIRE
Genentech`s Oncology Boss Jumps Ship to Helm Bellicum (BLCM)
01 Feb 2017 //
BIOSPACE
Cell preservation prosperity: BioLife and Cryoport up on personalised meds
20 Jan 2017 //
BIOPHARMA REPOTER
Juno Needs to Back a Different CAR-T Horse
06 Dec 2016 //
BLOOMBERG
Foresite Capital reloads with a $450M biotech venture fund
29 Jul 2015 //
FIERCE BIOTECH
As ASCO Primer: Which Drug Makers are Pursuing Which Kinds of Therapies
29 May 2015 //
PHARMALOT
Juno beefs up its CAR-T arsenal with an $80M biotech buyout
13 May 2015 //
FIERCE BIOTECH
Adaptimmune hauls in $191M in an upsized immuno-oncology IPO
06 May 2015 //
FIERCE BIOTECH
Juno and Novartis settle CAR-T patent fight with little fanfare
07 Apr 2015 //
FIERCE BIOTECH
High-flying immuno-oncology player Adaptimmune pitches $150M IPO
06 Apr 2015 //
FIERCE BIOTECH
